Pfizer Inc. has withdrawn an application seeking U.S. regulatory approval to market its antidepressant Pristiq as a treatment for certain menopause-related symptoms in women. The U.S. Food and Drug Administration in September declined to approve Pfizer's bid to expand the drug's uses to include relief of moderate-to-severe vasomotor symptoms associated with menopause, such as hot flashes and night sweats.The New York drug maker withdrew its FDA application earlier in February, Pfizer said in an annual report filed Tuesday with the Securities and Exchange Commission.
